Others

2-Azido-adenosine is a click chemistry reagent containing an azide group. 2-Azido-adenosine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

17-Aminogeldanamycin is an active compound.

Mono-Cyclohexyl Phthalate-3,4,5,6-d₄ is the deuterium labeled Mono-Cyclohexyl Phthalate.

Glufosinate-d₃ (hydrochloride) is a deuterium labeled compound.

JB061 is a nonmuscle myosin inhibitor with IC₅₀s of 4.4 μM (Cardiac muscle myosin), 9.1 μM (Skeletal muscle myosin), and >100 μM (Smooth muscle myosin II), respectively. JB061 poorly decreases ATPase activity (IC₅₀>200 μM). JB061 shows cytotoxicity against COS-7 cells with an IC₅₀ value of 39 μM.

YEATS4-IN-1 (Compound 4d) is a potent and selective YEATS4 binder that binds to the KAc recognition site of the YEATS structural domain with a K_i value of 33 nM.

2-Cyanoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.

Adenosine-2-carboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.

N3-Methyl-2’-O-methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents.

3’-O-(2-Methoxyethyl)adenosine is an adenosine analogue. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression. The popular products in this series are adenosine phosphate, Acadesine (HY-13417), Clofarabine (HY-A0005), Fludarabine phosphate (HY-B0028) and Vidarabine (HY-B0277).

3’-Deoxy-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.

N4-Methyl-2’-O-methyl-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.

6-Methyluridine is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents.

2’,3’-Dideoxy-3’-fluorocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc.

7-Deazaguanosine is a purine nucleoside analogue with antitrypanosomal activity.

2-Chloro-2′-β-C-methyladenosine is an adenosine analogue. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression. The popular products in this series are adenosine phosphate, Acadesine (HY-13417), Clofarabine (HY-A0005), Fludarabine phosphate (HY-B0028) and Vidarabine (HY-B0277).

7-Cyano-7-deaza-2'-deoxy guanosine is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7).

2,3-Di(furan-2-yl)quinoxaline (Compound 5) is a quinoxaline exhibiting blue fluorescence. 2,3-Di(furan-2-yl)quinoxaline is cell permeable and sufficiently bright at a micromolar concentration (1.5 μM).

Activated EG3 Tail can be used in the synthesis of exon jumping oligomer conjugates.

ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.